Does the media refer more to RVMD or ARWR?

In the previous week, Revolution Medicines had 14 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 18 mentions for Revolution Medicines and 4 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.12 beat Revolution Medicines' score of 0.36 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ONC or ARWR?

In the previous week, BeOne Medicines had 6 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 10 mentions for BeOne Medicines and 4 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.12 beat BeOne Medicines' score of 0.92 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARWR or BNTX?

In the previous week, BioNTech had 1 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 5 mentions for BioNTech and 4 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.12 beat BioNTech's score of 0.54 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARWR or INSM?

In the previous week, Insmed had 17 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 21 mentions for Insmed and 4 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.12 beat Insmed's score of 0.84 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 13 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Arrowhead Pharmaceuticals (ARWR) Competitors

$73.09 -2.07 (-2.75%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$73.20 +0.11 (+0.15%)

As of 06/5/2026 07:33 PM Eastern

Compare

ARWR vs. TEVA, RVMD, ONC, BNTX, and INSM

Should you buy Arrowhead Pharmaceuticals stock or one of its competitors? MarketBeat compares Arrowhead Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arrowhead Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), Revolution Medicines (RVMD), BeOne Medicines (ONC), BioNTech (BNTX), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

How does Arrowhead Pharmaceuticals compare to Teva Pharmaceutical Industries?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Arrowhead Pharmaceuticals presently has a consensus price target of $87.80, indicating a potential upside of 20.13%. Teva Pharmaceutical Industries has a consensus price target of $41.78, indicating a potential upside of 22.11%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Teva Pharmaceutical Industries had 25 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 29 mentions for Teva Pharmaceutical Industries and 4 mentions for Arrowhead Pharmaceuticals. Teva Pharmaceutical Industries' average media sentiment score of 1.16 beat Arrowhead Pharmaceuticals' score of 1.12 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	22 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Teva Pharmaceutical Industries has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	12.41	-$1.63M	-$2.15	N/A
Teva Pharmaceutical Industries	$17.26B	2.28	$1.41B	$1.33	25.72

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Summary

Teva Pharmaceutical Industries beats Arrowhead Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Arrowhead Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,739.75	-$1.13B	-$7.07	N/A
Arrowhead Pharmaceuticals	$829.45M	12.41	-$1.63M	-$2.15	N/A

In the previous week, Revolution Medicines had 14 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 18 mentions for Revolution Medicines and 4 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.12 beat Revolution Medicines' score of 0.36 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

Revolution Medicines has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Revolution Medicines currently has a consensus price target of $123.72, indicating a potential downside of 17.09%. Arrowhead Pharmaceuticals has a consensus price target of $87.80, indicating a potential upside of 20.13%. Given Arrowhead Pharmaceuticals' higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Arrowhead Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Revolution Medicines beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

BeOne Medicines currently has a consensus target price of $390.00, suggesting a potential upside of 44.39%. Arrowhead Pharmaceuticals has a consensus target price of $87.80, suggesting a potential upside of 20.13%. Given BeOne Medicines' stronger consensus rating and higher possible upside, equities analysts clearly believe BeOne Medicines is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Arrowhead Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

BeOne Medicines has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.55	$286.93M	$4.47	60.43
Arrowhead Pharmaceuticals	$829.45M	12.41	-$1.63M	-$2.15	N/A

BeOne Medicines has a net margin of 8.94% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. BeOne Medicines' return on equity of 12.06% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

In the previous week, BeOne Medicines had 6 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 10 mentions for BeOne Medicines and 4 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.12 beat BeOne Medicines' score of 0.92 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BeOne Medicines beats Arrowhead Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to BioNTech?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

BioNTech has a net margin of -44.39% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. BioNTech's return on equity of -5.30% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
BioNTech	-44.39%	-5.30%	-4.62%

Arrowhead Pharmaceuticals currently has a consensus price target of $87.80, suggesting a potential upside of 20.13%. BioNTech has a consensus price target of $129.56, suggesting a potential upside of 47.10%. Given BioNTech's higher probable upside, analysts clearly believe BioNTech is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Arrowhead Pharmaceuticals has higher earnings, but lower revenue than BioNTech. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	12.41	-$1.63M	-$2.15	N/A
BioNTech	$3.25B	6.86	-$1.29B	-$5.88	N/A

In the previous week, BioNTech had 1 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 5 mentions for BioNTech and 4 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.12 beat BioNTech's score of 0.54 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market.

Summary

BioNTech beats Arrowhead Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Insmed?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Arrowhead Pharmaceuticals has higher revenue and earnings than Insmed. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	12.41	-$1.63M	-$2.15	N/A
Insmed	$606.42M	33.68	-$1.28B	-$5.75	N/A

Arrowhead Pharmaceuticals presently has a consensus price target of $87.80, indicating a potential upside of 20.13%. Insmed has a consensus price target of $210.50, indicating a potential upside of 123.41%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to Insmed's net margin of -144.44%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Insmed	-144.44%	-130.11%	-51.57%

Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, Insmed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

In the previous week, Insmed had 17 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 21 mentions for Insmed and 4 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.12 beat Insmed's score of 0.84 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	13 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arrowhead Pharmaceuticals beats Insmed on 10 of the 16 factors compared between the two stocks.

Get Arrowhead Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARWR vs. The Competition

Export

Metric	Arrowhead Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.30B	$3.34B	$6.66B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.55%
P/E Ratio	-34.00	10.33	20.31	21.86
Price / Sales	12.41	300.34	516.18	112.47
Price / Cash	612.14	51.45	26.99	37.22
Price / Book	20.08	7.97	10.24	6.66
Net Income	-$1.63M	$23.89M	$3.57B	$337.55M
7 Day Performance	-6.19%	-6.96%	-1.28%	-2.52%
1 Month Performance	-6.23%	-2.80%	1.38%	-0.03%
1 Year Performance	334.80%	36.80%	23.93%	25.34%

Arrowhead Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARWR Arrowhead Pharmaceuticals	2.8703 of 5 stars	$73.09 -2.8%	$87.80 +20.1%	+334.8%	$10.30B	$829.45M	N/A	400	Positive News
TEVA Teva Pharmaceutical Industries	4.8513 of 5 stars	$34.51 -2.3%	$41.78 +21.1%	+92.6%	$40.61B	$17.35B	25.95	33,950	Trending News Analyst Upgrade
RVMD Revolution Medicines	2.105 of 5 stars	$163.68 +3.9%	$122.78 -25.0%	+263.2%	$33.48B	$11.58M	N/A	250	News Coverage Analyst Forecast Analyst Revision High Trading Volume
ONC BeOne Medicines	4.637 of 5 stars	$279.68 -2.9%	$389.15 +39.1%	+5.6%	$31.59B	$5.34B	62.57	12,000	Analyst Forecast
BNTX BioNTech	3.8842 of 5 stars	$91.70 -4.4%	$129.56 +41.3%	-18.8%	$24.26B	$3.25B	N/A	7,807	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARWR) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arrowhead Pharmaceuticals (ARWR) Competitors

ARWR vs. TEVA, RVMD, ONC, BNTX, and INSM

How does Arrowhead Pharmaceuticals compare to Teva Pharmaceutical Industries?

Summary

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Summary

How does Arrowhead Pharmaceuticals compare to BeOne Medicines?

Summary

How does Arrowhead Pharmaceuticals compare to BioNTech?

Summary

How does Arrowhead Pharmaceuticals compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR vs. The Competition

Arrowhead Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arrowhead Pharmaceuticals (ARWR) Competitors

ARWR vs. TEVA, RVMD, ONC, BNTX, and INSM

How does Arrowhead Pharmaceuticals compare to Teva Pharmaceutical Industries?

Do analysts rate ARWR or TEVA?

Does the media favor ARWR or TEVA?

Which has more risk & volatility, ARWR or TEVA?

Do insiders and institutionals believe in ARWR or TEVA?

Which has preferable valuation and earnings, ARWR or TEVA?

Is ARWR or TEVA more profitable?

Summary

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Do insiders & institutionals believe in RVMD or ARWR?

Which has better valuation and earnings, RVMD or ARWR?

Does the media refer more to RVMD or ARWR?

Which has more risk & volatility, RVMD or ARWR?

Is RVMD or ARWR more profitable?

Do analysts prefer RVMD or ARWR?

Summary

How does Arrowhead Pharmaceuticals compare to BeOne Medicines?

Do analysts prefer ONC or ARWR?

Which has stronger valuation & earnings, ONC or ARWR?

Is ONC or ARWR more profitable?

Do insiders and institutionals hold more shares of ONC or ARWR?

Which has more volatility and risk, ONC or ARWR?

Does the media favor ONC or ARWR?

Summary

How does Arrowhead Pharmaceuticals compare to BioNTech?

Is ARWR or BNTX more profitable?

Do analysts recommend ARWR or BNTX?

Do institutionals & insiders hold more shares of ARWR or BNTX?

Which has stronger earnings & valuation, ARWR or BNTX?

Does the media refer more to ARWR or BNTX?

Which has more risk & volatility, ARWR or BNTX?

Summary

How does Arrowhead Pharmaceuticals compare to Insmed?

Which has higher valuation and earnings, ARWR or INSM?

Do analysts prefer ARWR or INSM?

Do institutionals and insiders have more ownership in ARWR or INSM?

Is ARWR or INSM more profitable?

Which has more risk and volatility, ARWR or INSM?

Does the media prefer ARWR or INSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR vs. The Competition

Arrowhead Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools